Clinical Trials

Accrual Status
Limit to SWOG Trials

1033 Results

View
Open
Phase
Accrual
98%
SWOG Clinical Trial Number
S1609

DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Status Notes
Permanently Closed to Accrual: 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53.

Temporarily Closed to Accrual: 40, 46.

For the PD-L1 amplified cohort, patients do NOT need to qualify under one of the applicable histologies listed in Section 18.1.

Patients may now be registered directly to S1609 without having to be enrolled on EAY131 ("NCI-MATCH"). See Revision #3 for details.


Research Committee(s)
Early Therapeutics & Rare Cancers
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Lung Cancer
Melanoma
Activated
01-13-2017
ClinicalTrials.gov Registry Number
02834013
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1512

A Phase II Study of PD-1 Blockade with Pembrolizumab In Patients with Locally Advanced and Metastatic Desmoplastic Melanoma (DM)
Status Notes
This study will permanently close to accrual, effective 6/4/21.
Research Committee(s)
Melanoma
Activated
10-20-2016
ClinicalTrials.gov Registry Number
NCT #02775851
Closed
Phase
Accrual
93%
SWOG Clinical Trial Number
S1415CD

A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER)
Status Notes
This study was permanently closed to accrual effective 4/15/20.
Research Committee(s)
Cancer Care Delivery
Activated
10-07-2016
ClinicalTrials.gov Registry Number
NCT02728596
Closed
Phase
Accrual
86%
SWOG Clinical Trial Number
S1513

Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC- 737664) in Metastatic Pancreatic Cancer
Status Notes
Effective Immediately (12/13/2017) S1513 is permanently closed. Patients currently receiving ABT-888 (Veliparib) must discontinue the experimental treatment but may continue on FOLFIRI alone. Patients on both arms should continue study follow-up.
Research Committee(s)
Gastrointestinal Cancer
Activated
09-01-2016
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1507

A Phase II Trial Of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies.
Status Notes
This study permanently closed to accrual on March 15, 2018.
Research Committee(s)
Lung Cancer
Activated
07-18-2016
Closed
03-15-2018
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1416

Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer (TNBC) and/or BRCA Mutation-Associated Breast Cancer, with or without Brain Metastases
Status Notes
S1416 will permanently close to accrual on 6/15/19.
Research Committee(s)
Breast Cancer
Activated
07-07-2016
Closed
06-15-2019
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1417CD

Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer
Research Committee(s)
Cancer Care Delivery
Gastrointestinal Cancer
Activated
04-15-2016
Closed
02-01-2019
ClinicalTrials.gov Registry Number
NCT02728804
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1500

A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511])in Metastatic Papillary Renal Carcinoma (PAPMET)
Status Notes
Arms 3 and 4 of the study referenced above are permanently closed to accrual effective 12/5/18. Arms 1 and 2 are active to accrual effective 1/22/19.

Research Committee(s)
Genitourinary Cancer
Activated
04-05-2016
ClinicalTrials.gov Registry Number
NCT02761057
Closed
Phase
Accrual
79%
SWOG Clinical Trial Number
S1400I

A BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER - A PHASE III RANDOMIZED STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS NIVOLUMAB FOR PREVIOUSLY TREATED PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER AND NO MATCHING BIOMARKER
Status Notes
Effective 3:00 p.m. Pacific Time on April 23, 2018, S1400I will be permanently closed to accrual.

This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
12-18-2015
Closed
04-23-2018
Closed
Phase
Accrual
98%
SWOG Clinical Trial Number
S1404

A Phase III Randomized Trial of Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High-Risk Resected Melanoma -
Status Notes
Step 2 (randomization) of the above-referenced study will be permanently closed to accrual effective November 2, 2017 at 11:59 p.m. Pacific Time.

Closure to Step 1 (prestudy screening) was effective August 15th.



NOTE: This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Melanoma
Symptom Control and Quality of Life
Activated
10-15-2015
ClinicalTrials.gov Registry Number
NCT02506153
Closed
Phase
Accrual
98%
SWOG Clinical Trial Number
S1505

A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Status Notes
S1505 is now closed to accrual as of 04/20/2018.
Research Committee(s)
Gastrointestinal Cancer
Activated
10-12-2015
ClinicalTrials.gov Registry Number
NCT02562716
Closed
Phase
Accrual
29%
SWOG Clinical Trial Number
S1403

A Randomized Phase II Trial of Afatinib Plus Cetuximab Versus Afatinib Alone In Treatment-Naïve Patients With Advanced, EGFR Mutation Positive Non-Small Lung Cancer (NSCLC)
Status Notes
This study permanently closed to accrual effective April 23, 2018.
Research Committee(s)
Lung Cancer
Activated
03-25-2015
Closed
04-23-2018
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1316

Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction
Status Notes
Re-Activation - Effective 6/1/18
Research Committee(s)
Cancer Survivorship
Gastrointestinal Cancer
Activated
03-09-2015
ClinicalTrials.gov Registry Number
NCT02270450
Closed
Phase
Accrual
98%
SWOG Clinical Trial Number
S1318

A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia Chromosome Negative (Ph-) Acute Lymphocytic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dastainib-Sensitive Mutations or Kinase Fusions (DSMKF)
Research Committee(s)
Leukemia
Activated
01-12-2015
Closed
09-29-2021
ClinicalTrials.gov Registry Number
02143414
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1406

Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
11-13-2014
Closed
04-01-2016
ClinicalTrials.gov Registry Number
NCT02164916
Closed
Phase
Accrual
1%
SWOG Clinical Trial Number
S1300

A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit from Crizotinib Monotherapy
Status Notes
This study will permanently close to accrual on September 1, 2016 at 11:59 p.m. Pacific.
Research Committee(s)
Lung Cancer
Activated
08-01-2014
Closed
09-01-2016
ClinicalTrials.gov Registry Number
NCT #02134912
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1320

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing Of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma
Status Notes
Effective 7/15/2019, Step 2 registration (randomization) is permanently closed to accrual.

<b>Effective 4/19/19, Step 1 (lead‐in continuous dosing) will be permanently closed to accrual effective April 19, 2019 at 11:59 p.m. Pacific Time.

All patients who have consented must be registered to Step 1 (lead‐in continuous dosing) prior to 11:59 p.m. PT on April 19, 2019 in order to be eligible to participate. This closure does not apply to Step 2 randomization</b>
Research Committee(s)
Melanoma
Activated
07-22-2014
Closed
07-15-2019
ClinicalTrials.gov Registry Number
NCT02199730
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1314

A Randomized Phase II Study of CO-eXpression ExtrapolatioN (COXEN)-Directed Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Research Committee(s)
Genitourinary Cancer
Activated
07-09-2014
Closed
12-01-2017
ClinicalTrials.gov Registry Number
NCT02177695
Closed
Phase
SWOG Clinical Trial Number
S1400

A BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER (LUNG-MAP)
Status Notes
The S1400 screening protocol will close to accrual and be replaced by the new Lung-MAP screening protocol, called LUNGMAP, which will open to accrual January 28, 2019, effective 2:00 pm PST.

This is a potential FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Head and Neck Cancer
Lung Cancer
Activated
06-15-2014
ClinicalTrials.gov Registry Number
NCT02154490
Closed
Phase
Accrual
83%
SWOG Clinical Trial Number
S1400A

A BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER (LUNG-MAP) - A PHASE II STUDY OF MEDI4736 FOR PREVIOUSLY TREATED PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER AND NO MATCHING BIOMARKERS (LUNG-MAP SUB-STUDY)
Status Notes
This sub-study will be permanently closed to accrual on 12/18/15 at 2:00 p.m. Pacific
Research Committee(s)
Lung Cancer
Activated
06-15-2014
Closed
11-18-2015